Published in Hepatitis Weekly, December 23rd, 1996
"The excellent safety record of MF59 adjuvant with herpes simplex virus, HIV, influenza, and cytomegalovirus vaccines in humans and the dramatic immunogenicity provided by MF59 with hepatitis B virus (HBV) vaccine in the primate model make it a good candidate for an improved HBV vaccine," researcher Paula Traquina and colleagues wrote ("MF59 Adjuvant Enhances the Antibody Response to Recombinant Hepatitis B Surface Antigen Vaccine in Primates," Journal of Infectious Diseases, December 1996;174:1168-1175).
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Hepatitis Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.